ES-Park: Parkinson Specialized Teams Intervention

Migration, Crosslink

📖

ES-Park: Parkinson Specialized Teams Intervention

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-espark-pd-nct054334

📖 Wiki Page

clinical1520 wordssynced 2026-04-02

ES-Park: Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

Overview

flowchart TD clinical_trials_espark_pd_nct0["ES-Park: Parkinson Specialized Teams Interventio"] style clinical_trials_espark_pd_nct0 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_espa_0["Trial Details"] clinical_trials_espark_pd_nct0 -->|"includes"| clinical_trials_espa_0 style clinical_trials_espa_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_espa_1["Intervention Description"] clinical_trials_espark_pd_nct0 -->|"includes"| clinical_trials_espa_1 style clinical_trials_espa_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_espa_2["ESPark Team Components"] clinical_trials_espark_pd_nct0 -->|"includes"| clinical_trials_espa_2 style clinical_trials_espa_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_espa_3["Session Structure"] clinical_trials_espark_pd_nct0 -->|"includes"| clinical_trials_espa_3 style clinical_trials_espa_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_espa_4["Study Arms"] clinical_trials_espark_pd_nct0 -->|"includes"| clinical_trials_espa_4 style clinical_trials_espa_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_espa_5["Primary Endpoints"] clinical_trials_espark_pd_nct0 -->|"includes"| clinical_trials_espa_5 style clinical_trials_espa_5 fill:#81c784,stroke:#333,color:#000

...

ES-Park: Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

Overview

Mermaid diagram (expand to render)

ES-Park (Evaluation de l'Effectivité des Équipes Spécialisées Parkinson) is a pilot interventional study evaluating whether a multidisciplinary specialized Parkinson's team (Équipe Spécialisée Parkinson, ESPark) can improve quality of life for patients with moderate to severe Parkinson's disease through home-based rehabilitation and support["@ctgov"].

The trial is modeled on the successful French Équipes Spécialisées Alzheimer (ESA) model, which demonstrated positive outcomes for autonomy and resocialization in Alzheimer's disease. ES-Park adapts this multidisciplinary team approach specifically for Parkinson's disease patients, recognizing that the complexity of PD — spanning motor symptoms, non-motor features, psychosocial challenges, and caregiver burden — requires coordinated care beyond standard medical management.

Trial Details

| Parameter | Details |
|-----------|--------|
| Phase | Not Applicable (Pilot/Health Services Research) |
| NCT Number | NCT05433441 |
| Status | Recruiting |
| Sponsor | University Hospital, Bordeaux |
| Study Design | Randomized, crossover, open-label |
| Allocation | Randomized |
| Intervention Model | Crossover (standard care vs ESPark) |
| Masking | None (open-label) |
| Enrollment | 250 estimated |
| Start Date | December 6, 2022 |
| Primary Completion | December 6, 2025 |
| Study Completion | June 6, 2027 |
| Study ID | CHUBX 2022/02 |

Intervention Description

The ESPark Intervention is a 15-session home-based multidisciplinary program delivered once per week by a specialized Parkinson's team. Each session is tailored to the individual patient following an initial assessment.

ESPark Team Components

The ESPark team provides:

Functional rehabilitation: Exercises and strategies to maintain activities of daily living and mobility
Environmental optimization: Assessment and adaptation of the patient's living environment to maximize safety and independence
Care coordination: Integration with medical care and implementation of necessary assistive aids
Caregiver support: Training and support for the primary non-professional caregiver
Social reintegration: Strategies to maintain social connections and community participation

Session Structure

Initial Assessment (Session 1): Comprehensive evaluation to determine personalized objectives and follow-up plan

14 Weekly Sessions: Ecologically-based rehabilitation in the patient's home environment

Coordination: Integration with ongoing medical and physiotherapy care

Study Arms

| Arm | Type | Description |
|-----|------|-------------|
| Standard Care | No Intervention | Patients continue receiving routine medical and paramedical care |
| ESPark Intervention | Experimental | 15-session home-based multidisciplinary team program in addition to standard care |

Primary Endpoints

Quality of Life (PDQ-39)

Measure: Parkinson's Disease Questionnaire-39 (PDQ-39)
Timepoints: Baseline (Day 0), 6 months
Scoring: 39 items across 8 dimensions (activities of daily living, emotional well-being, stigma, social support, cognition, communication, bodily discomfort, mobility). Total score ranges from 0 (no disturbance) to 156 (maximum disturbance). Lower scores indicate better quality of life.

Secondary Endpoints

Functional Independence

| Measure | Description | Timepoints |
|---------|-------------|------------|
| IADL | Instrumental Activities of Daily Living scale (9 items, score 0-36) | Day 0, 6 months, 12 months |

Motor Assessment

| Measure | Description | Timepoints |
|---------|-------------|------------|
| MDS-UPDRS Part III | Motor examination subscale — speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination, toe tapping, leg agility, chair rise, gait, postural stability, posture, tremor (rest/action/amplitude/constancy), dyskinesia assessment, Hoehn & Yahr staging | Day 0, 6 months, 12 months |

Non-Motor Symptoms

| Measure | Description | Timepoints |
|---------|-------------|------------|
| NMSS | Non-Motor Symptoms Scale for Parkinson's Disease (30 items, 9 dimensions) | Day 0, 6 months, 12 months |

Cognitive Assessment

| Measure | Description | Timepoints |
|---------|-------------|------------|
| MoCA | Montreal Cognitive Assessment (30-point scale; 27-30: normal, 18-26: mild cognitive impairment, 10-17: moderate, <10: severe) | Day 0, 6 months, 12 months |

Psychological Outcomes

| Measure | Description | Timepoints |
|---------|-------------|------------|
| BDI-II | Beck Depression Inventory — 21 items, somatic/affective/cognitive symptoms, past 7 days, 0-63 scale (higher = more severe) | Day 0, 6 months |

Caregiver Outcomes

| Measure | Description | Timepoints |
|---------|-------------|------------|
| PQoL Carers | Parkinson's Disease Quality of Life Questionnaire for Caregivers — 26 items, total score 0-104 | Day 0, 6 months, 12 months |
| SCQ | Sense of Competence Questionnaire — 35 items across 3 domains (caregiving impact, performance satisfaction, care recipient satisfaction), scored 1-3 (27-81 scale) | Day 0, 6 months, 12 months |

Health Economics

| Measure | Description | Timepoints |
|---------|-------------|------------|
| RUD | Resource Utilization in Dementia — evaluates formal resources (social services, home care) and informal resources (caregiver time), valued at health insurance rates | Day 0, 6 months, 12 months |

Eligibility Criteria

Inclusion Criteria

Patient:

Diagnosis of idiopathic Parkinson's disease
Age 18 years or older
Hoehn and Yahr Stage ≥ 3 (moderate to severe disease)
MoCA score ≥ 21 (no major cognitive impairment)
Living at home
Has an identified non-professional primary caregiver
Affiliated with or benefiting from a social security plan
Written informed consent

Caregiver:

Age 18 years or older
Able to respond to research interviews/questionnaires
Written informed consent

Exclusion Criteria

Patient:

Medically indicated dementia impairing comprehension and adherence, or severe confusion/psycho-hallucinatory state
Institutionalized or in foster care
Known severe and unstable general pathology preventing follow-up
Currently enrolled in another non-drug management trial
Institutionalization or change of residence planned within 6 months
Under guardianship or unable to express consent
Primary caregiver unwilling or unavailable for study follow-up
Primary caregiver with known severe/unstable disease or cognitive/psychiatric disorder preventing study participation
Pregnant or breastfeeding

Caregiver:

Unable to follow research interviews/questionnaires
Unwilling or unavailable for planned follow-up
Known severe/unstable illness or cognitive/psychiatric disorder preventing proper study conduct

Study Sites

| Site | City | Status | Contact |
|------|------|--------|---------|
| Hôpital Pellegrin (CHU de Bordeaux) | Bordeaux | Recruiting | Dr. Alexandra Foubert-Samier |
| CHU de Lille | Lille | Recruiting | Dr. Nicolas Carriere |
| CHU de Limoges | Limoges | Recruiting | Pr. Jean-Luc Houeto |
| CHU Poitiers | Poitiers | Recruiting | Dr. Isabelle Benatru |

Principal Investigator

Dr. Alexandra Foubert-Samier
University Hospital, Bordeaux

Relevance to Parkinson's Disease Care

The Case for Multidisciplinary PD Teams

Parkinson's disease is a complex multifactorial disorder requiring coordinated care across multiple domains:

Motor symptoms: Tremor, bradykinesia, rigidity, postural instability
Non-motor symptoms: Depression, anxiety, cognitive impairment, sleep disorders, autonomic dysfunction, pain
Functional decline: Progressive loss of activities of daily living and social participation
Caregiver burden: High stress and reduced quality of life among caregivers

Standard care often addresses these domains in fragmented ways — neurology visits for medication adjustment, physiotherapy for mobility, psychiatry separately for mood, with limited coordination. The ESPark model seeks to integrate these elements through a single specialized team working in the patient's home environment.

Comparison to ESA (Équipes Spécialisées Alzheimer)

The ESPark model directly adapts the French ESA framework that demonstrated positive outcomes in Alzheimer's disease. The ESA teams showed improvements in:

Patient autonomy and functional independence
Caregiver quality of life and sense of competence
Reduced institutionalization rates
Better coordination of care

ES-Park tests whether these benefits extend to PD, where the symptom profile (prominent motor disability, levodopa-induced fluctuations, distinct non-motor features) differs from Alzheimer's disease.

Home-Based Ecological Approach

The home-based delivery is a key feature of the ESPark intervention:

Ecological validity: Rehabilitation occurs in the patient's actual living environment
Personalization: Interventions can be directly tailored to actual daily life challenges
Environmental modification: The team can identify and implement home adaptations
Caregiver integration: Training occurs where care is actually delivered

Scientific Context

Health Services Research in PD

ES-Park falls within health services research — evaluating not a drug or device, but a care delivery model. This type of trial addresses:

Effectiveness (real-world outcomes) vs. efficacy (controlled trial outcomes)
Cost-effectiveness and resource utilization
Patient and caregiver-reported outcomes
Implementation science

Methodological Considerations

The crossover design allows each patient to serve as their own control, which can:

Reduce confounding from between-patient variability
Require smaller sample sizes for equivalent statistical power
But: may be affected by carryover effects if the intervention period is long

The open-label design is appropriate for a behavioral/care delivery intervention where blinding participants and providers is not feasible.

Cross-References

[Parkinson's Disease Overview](/clinical-trials/parkinsons-disease) — broader PD trial landscape](/proteins/parkin)
[Exenatide Parkinson's Trial](/clinical-trials/exenatide-parkinsons) — GLP-1RA disease modification](/proteins/parkin)
[Buntanetap Phase 3 PD](/clinical-trials/buntanetap-phase3-pd-nct07284784) — alpha-synuclein aggregation inhibition

[Parkinson's Disease](/diseases/parkinsons-disease) — disease mechanism pages](/proteins/parkin)
[Parkinson's Disease Non-Motor Symptoms](/diseases/parkinsons-disease) — non-motor features

Multidisciplinary Care in Neurodegenerative Disease
Physical Therapy in Parkinson's Disease
Caregiver Support in Parkinson's Disease

References

[University Hospital Bordeaux, ES-Park Clinical Trial (NCT05433441) (2022)](/[https://clinicaltrials.gov/study/NCT05433441](https://clinicaltrials.gov/study/NCT05433441))

[PDQ-39: Parkinson's Disease Questionnaire — Movement Disorders](https://pubmed.ncbi.nlm.nih.gov/1409798/)

[Non-Motor Symptoms Scale (NMSS) for Parkinson's Disease — Chaudhuri et al.](https://pubmed.ncbi.nlm.nih.gov/17671201/)

[MDS-UPDRS: Movement Disorder Society Unified Parkinson's Disease Rating Scale — Goetz et al.](https://pubmed.ncbi.nlm.nih.gov/18649426/)

[MoCA: Montreal Cognitive Assessment — Nasreddine et al.](https://pubmed.ncbi.nlm.nih.gov/15976620/)

[Beck Depression Inventory II (BDI-II) — Beck et al.](https://pubmed.ncbi.nlm.nih.gov/9616598/)

[Resource Utilization in Dementia (RUD) — Wimo & Winblad](https://pubmed.ncbi.nlm.nih.gov/15128934/)

📖 View canonical wiki page →

Related Entities

clinical-trials-espark-pd-nct05433441

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-espark-pd-nct05433441
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b8b1f8a9a6a7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-espark-pd-nct05433441'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

25

Outgoing

53

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ES-Park: Parkinson Specialized Teams Intervention

ES-Park: Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

Overview

ES-Park: Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

Overview

Trial Details

Intervention Description

ESPark Team Components

Session Structure

Study Arms

Primary Endpoints

Quality of Life (PDQ-39)

Secondary Endpoints

Functional Independence

Motor Assessment

Non-Motor Symptoms

Cognitive Assessment

Psychological Outcomes

Caregiver Outcomes

Health Economics

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Study Sites

Principal Investigator

Relevance to Parkinson's Disease Care

The Case for Multidisciplinary PD Teams

Comparison to ESA (Équipes Spécialisées Alzheimer)

Home-Based Ecological Approach

Scientific Context

Health Services Research in PD

Methodological Considerations

Cross-References

References

💬 Discussion

📗 Cite This Artifact

ES-Park: Parkinson Specialized Teams Intervention

ES-Park: Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

Overview

ES-Park: Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

Overview

Trial Details

Intervention Description

ESPark Team Components

Session Structure

Study Arms

Primary Endpoints

Quality of Life (PDQ-39)

Secondary Endpoints

Functional Independence

Motor Assessment

Non-Motor Symptoms

Cognitive Assessment

Psychological Outcomes

Caregiver Outcomes

Health Economics

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Study Sites

Principal Investigator

Relevance to Parkinson's Disease Care

The Case for Multidisciplinary PD Teams

Comparison to ESA (Équipes Spécialisées Alzheimer)

Home-Based Ecological Approach

Scientific Context

Health Services Research in PD

Methodological Considerations

Cross-References

Related Clinical Trials

Related Conditions

Related Care Approaches

References

💬 Discussion